Form 4: INSMED Officer Reports Stock Sales, Option Grants

INSMED's Chief People Strategy Officer reported the exercise and sale of common stock, alongside new RSU and option grants, all executed under a pre-arranged 10b5-1 plan.

Summary

• Schaeffer Orlov S Nicole, Chief People Strategy Officer of INSMED Inc. (INSM), reported several transactions on January 2, 2026.
• Acquired 5,293 Restricted Stock Units (RSUs) for no consideration, which represent a contingent right to receive one share of Common Stock and vest over time.
• Exercised 87,290 stock options with an exercise price of $13.91.
• Sold a total of 87,290 shares of common stock in multiple transactions at weighted average prices ranging from $174.28 to $177.78.
• Received a new grant of 27,600 stock options with an exercise price of $177.12, which vest over time and expire on January 2, 2036.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 29, 2025.
• Beneficial ownership of common stock following these transactions is 41,754 shares.
• Beneficial ownership of derivative securities (stock options) following these transactions is 27,600.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions, including option exercises, stock sales, and new equity grants, all executed under a pre-arranged 10b5-1 plan. This is a standard practice for executive compensation and personal financial management, and does not inherently signal positive or negative company performance.

Positives

• Grant of 5,293 new Restricted Stock Units (RSUs) aligns executive interests with long-term shareholder value.
• Grant of 27,600 new stock options provides future incentive and compensation for the executive.
• All transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a structured and compliant approach to managing personal equity holdings.

Negatives

• Sale of 87,290 shares of common stock by a key executive, which could be perceived as a reduction in direct equity exposure, although it was part of a pre-planned strategy.

Risks

• While executed under a 10b5-1 plan, significant insider sales, even if pre-planned, can sometimes be misinterpreted by the market as a lack of confidence, potentially leading to minor, short-term negative sentiment.

Future Outlook

The newly granted Restricted Stock Units (RSUs) will vest 25% on the first day of the first month following the first anniversary of the grant date, and 25% on each subsequent anniversary until fully vested. The newly granted stock options will become exercisable with 25% vesting on the Initial Vesting Date and an additional 12.5% vesting every six months thereafter until fully vested.

Management Comments

• The transactions were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 29, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Industry Context

Routine insider transactions, such as option exercises and subsequent sales, are common in publicly traded companies as executives manage their equity compensation and diversify their personal portfolios. The use of a 10b5-1 plan is a standard and recommended practice to ensure compliance with insider trading regulations and demonstrate pre-planned activity.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor impact. The transactions are routine and pre-planned, reflecting executive compensation management rather than a change in company fundamentals or outlook.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact.

Next Steps

• Future vesting of 5,293 Restricted Stock Units (RSUs) according to their schedule.
• Future vesting of 27,600 stock options according to their schedule.

Key Dates

Keywords

INSMED, INSM, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, 10b5-1 Plan, Executive Compensation, Equity Sales